An-Najah University Journal for Research - A (Natural Sciences)

Pharmacological Evaluation of 5-Flurouracil (5-FU) ‎Utilization among Patients with Gastro-Intestinal Tract ‎‎(GIT) Cancers‎

Article info

2003-10-21
2004-05-23
2004-05-23
193 - 202

Keywords

Abstract

The clinical utilization of 5-Fluorouracil and its therapeutic implications were investigated at Al-Watani governmental hospital at Nablus (Palestine). The drug and disease profiles of one hundred and thirty patients suffering from various types of cancers were studied. No correlation was noticed between gender and cancer in general although such correlation might exist among patients with gastrointestinal tract (GIT) cancers. Approximately one third (29%) of those patients were suffering from (GIT) cancers especially colon and liver cancers. The majority (66%) of the patients with GIT cancers were treated with 5-FU. Leucovorin (LV) was used by (68%) of patients suffering from GIT cancers and were receiving 5-FU. Patients, in general, were not exposed to poly-chemotherapy (2.6 drugs/patient). Strong pain killers like morphine were used in approximately 24% of patients having GIT cancers. The utilization of 5-FU and LV is in agreement to the general international recommendations especially among patients with colon cancer. Further national studies are required to investigate cost/effectiveness, dose and drug appropriateness among patients with malignant diseases.

Recommended Citation

Sweileh, W., Jaradat, N., & Marmash, M. (2004). Pharmacological Evaluation of 5-Flurouracil (5-FU) Utilization among Patients with Gastro-Intestinal Tract (GIT) Cancers. An-Najah University Journal for Research - A (Natural Sciences), 18(2), 193–202. https://doi.org/10.35552/anujr.a.18.2.619
[1]W. Sweileh, N. Jaradat, and M. Marmash, “Pharmacological Evaluation of 5-Flurouracil (5-FU) Utilization among Patients with Gastro-Intestinal Tract (GIT) Cancers,” An-Najah University Journal for Research - A (Natural Sciences), vol. 18, no. 2, pp. 193–202, May 2004, doi: 10.35552/anujr.a.18.2.619.
Sweileh, Waleed, et al. “Pharmacological Evaluation of 5-Flurouracil (5-FU) Utilization among Patients with Gastro-Intestinal Tract (GIT) Cancers.” An-Najah University Journal for Research - A (Natural Sciences), vol. 18, no. 2, May 2004, pp. 193–202. Crossref, https://doi.org/10.35552/anujr.a.18.2.619.
1.Sweileh W, Jaradat N, Marmash M. Pharmacological Evaluation of 5-Flurouracil (5-FU) Utilization among Patients with Gastro-Intestinal Tract (GIT) Cancers. An-Najah University Journal for Research - A (Natural Sciences) [Internet]. 2004 May;18(2):193–202. Available from: http://dx.doi.org/10.35552/anujr.a.18.2.619
Sweileh, Waleed, Nidal Jaradat, and Mai Marmash. “Pharmacological Evaluation of 5-Flurouracil (5-FU) Utilization among Patients with Gastro-Intestinal Tract (GIT) Cancers.” An-Najah University Journal for Research - A (Natural Sciences) 18, no. 2 (May 2004): 193–202. https://doi.org/10.35552/anujr.a.18.2.619.

التقييم الدوائي لدواء

معلومات المقال

2003-10-21
2004-05-23
2004-05-23
193 - 202

الكلمات الإفتتاحية

الملخص

لقد تم بحث الاستعمال السريري والمغزى العلاجي لدواء فلورويراسيل في المستشفى الوطني الحكومي في مدينة نابلس في فلسطين، وتمت الدراسة على الملف الدوائي والمرضي لمائة وثلاثين مريضاً مصابين بالسرطان. لم تكن هنالك علاقة بين الإصابة بالسرطان وجنس المريض، مع أنه قد توجد مثل هذه العلاقة في حالة سرطان الجهاز الهضمي. وكان حوالي ثلث المرضى تقريباً (29%) يعانون من سرطان الجهاز الهضمي، وخاصة سرطان القولون والكبد. وكان معظم مرضى سرطان الجهاز الهضمي (66%) يتناولون دواء فلورويراسيل، كما أن 68% من هؤلاء المرضى كانوا يتناولون دواء لوكوفرين (LV). ولم يكن عند مرضى السرطان، بشكل عام، ظاهرة تعدد الأدوية، وانما كان معدل استهلاكهم للدواء 2.6 دواء لكل مريض. وقد استعملت المسكنات القوية مثل المورفين عند 24% من المرضى المصابين بسرطان الجهاز الهضمي. ويتفق استعمال دواء الفلورويراسيل والكوفرين مع التوصيات الدولية العامة، وخاصة في سرطان القولون وهناك حاجة إلى المزيد من الدراسات لتحديد الفعالية مقابل التكلفة، وكذلك دراسة الجرعة ونوعية الأدوية المستعملة وتعد مدى مناسبتها أمراً مطلوباً على المستوى الوطني.

Recommended Citation

Sweileh, W., Jaradat, N., & Marmash, M. (2004). Pharmacological Evaluation of 5-Flurouracil (5-FU) Utilization among Patients with Gastro-Intestinal Tract (GIT) Cancers. An-Najah University Journal for Research - A (Natural Sciences), 18(2), 193–202. https://doi.org/10.35552/anujr.a.18.2.619
[1]W. Sweileh, N. Jaradat, and M. Marmash, “Pharmacological Evaluation of 5-Flurouracil (5-FU) Utilization among Patients with Gastro-Intestinal Tract (GIT) Cancers,” An-Najah University Journal for Research - A (Natural Sciences), vol. 18, no. 2, pp. 193–202, May 2004, doi: 10.35552/anujr.a.18.2.619.
Sweileh, Waleed, et al. “Pharmacological Evaluation of 5-Flurouracil (5-FU) Utilization among Patients with Gastro-Intestinal Tract (GIT) Cancers.” An-Najah University Journal for Research - A (Natural Sciences), vol. 18, no. 2, May 2004, pp. 193–202. Crossref, https://doi.org/10.35552/anujr.a.18.2.619.
1.Sweileh W, Jaradat N, Marmash M. Pharmacological Evaluation of 5-Flurouracil (5-FU) Utilization among Patients with Gastro-Intestinal Tract (GIT) Cancers. An-Najah University Journal for Research - A (Natural Sciences) [Internet]. 2004 May;18(2):193–202. Available from: http://dx.doi.org/10.35552/anujr.a.18.2.619
Sweileh, Waleed, Nidal Jaradat, and Mai Marmash. “Pharmacological Evaluation of 5-Flurouracil (5-FU) Utilization among Patients with Gastro-Intestinal Tract (GIT) Cancers.” An-Najah University Journal for Research - A (Natural Sciences) 18, no. 2 (May 2004): 193–202. https://doi.org/10.35552/anujr.a.18.2.619.

An-Najah National University
Nablus, Palestine
P.O. Box
7, 707
Fax
(970)(9)2345982
Tel.
(970)(9)2345560
(970)(9)2345113/5/6/7-Ext. 2628
E-mail
[email protected]
EIC
Prof. Ismail Warad

An-Najah University Journal for Research - A (Natural Sciences) by An-Najah University, Nablus, Palestine is licensed under CC BY-NC 4.0